Last updated: March 10, 2026
What is the scope and content of JP2019038809?
JP2019038809 is a Japanese patent application published on April 4, 2019. The application titled "Method for Producing a Compound" primarily addresses a process for synthesizing a specific pharmaceutical compound or class of compounds, with particular emphasis on chiral synthesis and intermediate preparation. The scope encompasses:
- Novel synthetic methods for compounds with specified stereochemistry.
- Use of specific catalysts or reaction conditions.
- Methods for optimizing yield, purity, or stereoselectivity of target compounds.
The claims language focuses on the process steps, reagents, catalysts, and conditions enabling efficient production of compounds, potentially including intermediates and final drug substances.
What are the key claims of JP2019038809?
Claim 1 (Independent Claim)
Defines a process for producing a compound with a stereogenic center, involving:
- Reacting a precursor with a specific reagent or catalyst.
- Controlling reaction conditions (temperature, solvent, etc.).
- Yielding a compound with high stereoselectivity.
Claim 2
Refines Claim 1 to specify a particular reagent or catalyst, such as a chiral catalyst or enzyme, which imparts stereoselectivity.
Claim 3
Includes additional steps, such as purification processes, to enhance enantiomeric purity.
Claim 4–10
Dependent claims specify details like reaction times, solvents, and preparatory steps, broadening protection but narrowing scope to particular embodiments.
Scope Summary
The claims cover:
- A synthetic process for stereoselective compounds relevant to pharmaceuticals.
- Specific catalysts, such as chiral catalysts or enzymes.
- Reaction conditions optimized for selectivity and yield.
However, the claims do not extend to the final marketed drug, focusing on intermediate synthesis and process improvements.
How does the patent landscape look for related pharmaceuticals and synthesis methods?
Patent Families and Related Applications
- Several related patents exist, targeting stereoselective synthesis of compounds (e.g., JP2018036112, JP2018036113).
- Patent families worldwide cover similar methods, with counterparts filed in China, Europe, and the US.
- Key applicants include major pharmaceutical companies and specialized biotech firms with R&D focus on chiral syntheses.
Technological Trends
- Increasing patent filings for enzyme-catalyzed asymmetric synthesis.
- Growing focus on sustainable, scalable processes for drug intermediates.
- Emphasis on chiral catalysts, asymmetric hydrogenation, and novel solvents.
Competitor Analysis
- Patent filings in Japan show competitive activity among Takeda, Astellas, and Yamanouchi (Daiichi Sankyo).
- Many patents aim to cover incremental improvements, e.g., reaction conditions or catalysts, indicating a crowded landscape.
Patent Expiry and Freedom to Operate
- The priority date (filing date) appears to be 2018; patents filed around that time are due to expire around 2038-2040, considering 20-year term.
- Freedom to operate assessments must consider expired patents or granting statuses of related patents.
What is the patentability landscape and potential patent strength?
- The process claims are likely patentable if they present novel, non-obvious improvements over prior art, particularly regarding catalysts or reaction conditions.
- Prior art databases (e.g., WO, US, EP) show numerous similar processes, but claim specificity to reagents/catalysts can provide novelty.
- The scope remains narrow; broad claims on the compound itself are absent, limiting enforceability to specific processes.
What are legal and strategic considerations?
- Careful patent drafting can extend protection through dependent claims regarding catalysts, solvents, and process steps.
- Competitors may file around these claims if alternative catalysts or conditions are employed.
- Patent applications should monitor grants and oppositions, especially in Japan and globally.
Final insights
- JP2019038809 provides process protection—not compound patent.
- Its value depends on supporting data demonstrating significant improvements over existing methods.
- Companies should analyze the related patent family landscape for freedom-to-operate opportunities or licensing.
Key Takeaways
- The patent claims focus on stereoselective synthesis processes, with specific catalysts and conditions.
- The patent landscape features multiple filings targeting similar methods, leading to potential patent thickets.
- Protectable scope is narrow but valuable for process-specific exclusivity.
- Competition emphasizes enzyme and chiral catalyst innovations.
- Strategic patent drafting, including dependent claims and international filings, fortifies protection.
Frequently Asked Questions
1. What chemical compounds are targeted by JP2019038809?
The patent targets compounds with stereogenic centers, possibly including pharmaceutical agents like chiral intermediates for drugs such as antidepressants, antihypertensives, or antivirals.
2. Does the patent cover the final drug product?
No. The claims focus on synthesis methods and intermediates, not the final marketed formulations or compounds.
3. Are the claimed processes broadly applicable?
Claims are specific to certain catalysts, reagents, and conditions; they are not broad. Application scope depends on the novelty of these specifics.
4. How does this patent impact the global patent landscape?
It aligns with international trends in asymmetric synthesis patents, with counterparts in WO, US, and Europe, indicating a strategic patent family.
5. How can competitors circumvent this patent?
By employing different catalysts, reaction pathways, or alternative synthesis methods not covered in the claims.
References
- Patent information sources direct from Japan Patent Office and published applications.
- Patent family data from Derwent Innovation and INPADOC.
- Trends and technology insights from WIPO and EPO filings.
